Characterized and predictable rabbit uveitis model for antiinflammatory drug screening

Jamieson, Laura; Meckoll-Brinck, Donna; Keller, Nancy R.

doi:10.1016/0160-5402(89)90070-3

Cited by 7 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На відміну від загальноприйнятої терапії увеїтів (Jamieson, Meckoll-Brinck, & Keller, 1989;Shelley et al, 2012;Gulati, Pahuja, Fan, & Toris, 2012;Movafagh, Heydary, Mortazavi-Tabatabaei, & Azargashb, 2011;Ahmad, 2018) з використанням кортикостероїдів, застосування яких супроводжується рядом небажаних побічних ефектів (гальмування регенерації, пригнічення імунної функції тощо), провели апробацію лікування токсикоалергічного увеїту із використанням нестероїдних протизапальних препаратів.…”

Section: вступunclassified

Modelling and treatment of the uveitis in rabbit

Doroshchuk¹

2019

VTTP

View full text Add to dashboard Cite

Modelling of the toxico-allergic uveitis is better conducted on rabbits. For the treatment, contrary to corticosteroids that generate a number of side effects (e.g. suppression of reaction, immune inhibitions etc.), one can successfully use nonsteroid drugs, particularly Voltaren and Vetofluxin, which render phagocytes stimulation and immunoglobulin control. As a result, use of these drugs brings to recovery within 7 days. The decrease in the level of immunoglobulins in the blood serum during the treatment of uveitis compared with levels untreated animals was accompanied by a sharp attenuation of the inflammatory response in the blood test and taking into account the features of immunological protection of the eye (the presence of blood-ocular barrier between blood and chamber moisture, vascular membrane, retina, vitreous body) it should be emphasized that the body as a whole responds to the inflammatory process in the uveal tract. Considering toxico-allergic uveitis as an autoimmune disease and in respect that the positive effects of the drugs used on inflammatory and allergic processes, we can predict that the drugs we use are able to participate in the regulation of antibody-forming function of Bcells and inhibite autoimmune disorders. Both treatment schemes show the stimulating effect on phagocytosis, comparing with using phytohemagglutinin, which show no effect. In experimental toxico-allergic uveitis, the treatment regimen in the first experimental group not only did not reduce, but moreover, retained the potential effect on the phagocytic activity of leukocytes. Compared with phytohemagglutinin impact on phagocytosis, found that both represented treatment strategies stimulate the phagocytosis. In experimental toxico-allergic uveitis, Voltaren and Vetofluxin not only did not reduce, as is usually the case with corticosteroids, but moreover, clearly showed a stimulating effect on the phagocytic activity of peritoneal macrophages. Thus, studies have shown that in the treatment of such a severe inflammatory process as uveitis, in contrast to corticosteroids, the use of which is accompanied by a number of undesirable effects (inhibition of regeneration, inhibition of immune reactions, etc.), you can successfully use non-steroidal anti-inflammatory drugs, in particular Voltaren and Vetofluxin. The stimulating phagocytosis effect of Voltaren and Vetofluxin and ability to regulate the levels of immunoglobulins during inflammation has been established.

show abstract

Section: вступunclassified